In cases of CAO, in which FGF23 excess is caused by non-PMT solid or hematologic malignancies, the treatment approach involves targeting the underlying malignancy, while using medical therapies to manage the hypophosphatemia and symptoms. This evidence concerns the gene FGF23 and hypophosphatemia.